Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer

Shashank Sama; Sterling Rosqvist; Talicia Savage; Lesley Lomo; Kiera Sibbald; Alli Straubhar; Theresa L. Werner

Gynecologic Oncology Reports (Jun 2024)

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer

Shashank Sama,
Sterling Rosqvist,
Talicia Savage,
Lesley Lomo,
Kiera Sibbald,
Alli Straubhar,
Theresa L. Werner

Affiliations

Shashank Sama: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA; Corresponding author at: Huntsman Cancer Institute, 1950 Circle of Hope, 8203, Salt Lake City, UT 84112, USA.
Sterling Rosqvist: University of Utah, Salt Lake City, UT, USA
Talicia Savage: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
Lesley Lomo: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
Kiera Sibbald: University of Utah, Salt Lake City, UT, USA
Alli Straubhar: Intermountain Hospital, USA
Theresa L. Werner: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA

Journal volume & issue: Vol. 53
p. 101412

Abstract

Read online

Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and molecular characteristics as well as surgical considerations and ongoing investigations in LGSOC.

Published in Gynecologic Oncology Reports

ISSN: 2352-5789 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Gynecology and obstetrics; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/gynecologic-oncology-reports/

About the journal

Abstract

Keywords